Exceptional long-term survival in a patient with recurrent pancreatic carcinoma on adjuvant tegafur-gimeracil-oteracil potassium: a case report

一例接受替加氟-吉美嘧啶-奥替拉西钾辅助治疗的复发性胰腺癌患者获得长期生存的病例报告

阅读:1

Abstract

BACKGROUND: Pancreatic carcinoma is a highly malignant tumor, and it is aggressive even in its early stage. It has a very poor prognosis and responds poorly to systemic therapy. It is common for resected patients to undergo postoperative adjuvant chemotherapy. However, survival remains low, with an average 5-year survival of 10-25% and median survival between 10 and 20 months. CASE PRESENTATION: A 50-year-old Malaysian Chinese gentleman with no past medical history was diagnosed with stage IIb pancreatic cancer. A computed tomography scan of the abdomen showed a tumor at the uncinate lobe of the pancreatic head. He underwent a Whipple pancreaticoduodenectomy followed by postoperative chemotherapy with gemcitabine combined with 5-fluorouracil for 6 months. However, a rising carbohydrate antigen 19-9 level and a positron emission tomography-computed tomography scan showing a (18)F-fluorodeoxyglucose avid focus above the resected pancreas led to a repeat laparotomy 10 months after the first surgery. Even though an omental tissue biopsy at the area of the hepatic flexure was normal, the CA19-9 level continued to increase, indicating tumor recurrence. Subsequently, the patient was treated with 25 fractions of radiotherapy to the peripancreatic lymph nodes followed by tegafur-gimeracil-oteracil potassium maintenance. He went on to achieve a progression-free survival of more than 5 years with good tolerability and no adverse drug induced reaction. More than 9 years into treatment, he continues to enjoy good health and quality of life and is tolerating the treatment well. CONCLUSION: This case shows an exceptional long-term survival of a patient with pancreatic cancer with early recurrence after adjuvant chemotherapy treated with maintenance tegafur-gimeracil-oteracil potassium.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。